HC Wainwright & Co. Reiterates Buy on AnaptysBio, Maintains $95 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 92.1%

Neg 0% Neu 92.1% Pos 0%

HC Wainwright & Co. analyst Joseph Pantginis reiterates AnaptysBio (NASDAQ:ANAB) with a Buy and maintains $95 price target.